Harmony Biosciences Holdings, Inc. Income Statement
HRMY / Health Care|7 years of annual SEC 10-K data (FY2019-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
Harmony Biosciences Holdings, Inc. reported $868M in revenue and $159M in net income for FY2025. Revenue has grown at a 129.2% compound annual rate over the past 6 years.
Based on SEC 10-K filings.
Key Data Points
- Strong profit margin: 20.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $868.5M | $714.7M | $582.0M | $437.9M | $305.4M | $6.0M | $6.0M |
| Cost of Revenue | $198.3M | $156.8M | $121.2M | $83.5M | $55.5M | $1.6M | $1.6M |
| Gross Profit | $670.1M | $557.9M | $460.8M | $354.4M | $249.9M | $4.4M | $4.4M |
| SG&A Expense | $152.5M | $110.4M | $95.3M | $84.0M | $63.9M | $36.4M | $36.4M |
| R&D Expense | $189.6M | $145.8M | $76.1M | $70.9M | $30.4M | $69.6M | $69.6M |
| Operating Income | $208.5M | $190.8M | $192.0M | $120.2M | $87.5M | -$145.9M | -$145.9M |
| Interest Expense | $14.6M | $17.5M | $23.8M | $18.8M | $24.2M | - | $7.4M |
| Income Tax | $56.4M | $46.3M | $44.5M | -$76.8M | $2.8M | - | - |
| Net Income | $158.7M | $145.5M | $128.9M | $181.5M | $34.6M | -$152.0M | -$152.0M |
| EPS (Basic) | $2.76 | $2.56 | $2.17 | -$2.48 | $0.60 | -$24.07 | -$24.07 |
| EPS (Diluted) | $2.71 | $2.51 | $2.13 | -$2.48 | $0.58 | -$24.07 | -$24.07 |
| Shares Outstanding | 57.7M | 57.1M | 56.8M | 58.8M | 58.8M | 7.8M | 7.8M |
| Gross Margin | 77.2% | 78.1% | 79.2% | 80.9% | 81.8% | 73.7% | 73.7% |
| Operating Margin | 24.0% | 26.7% | 33.0% | 27.5% | 28.7% | -2433.8% | - |
| Profit Margin | 18.3% | 20.4% | 22.1% | 41.4% | 11.3% | -2535.1% | - |